• Molecular NameDeferasirox
  • Synonymdeferasirox; Deferasiroxum [inn-latin]; ICL 670
  • Weight373.368
  • Drugbank_IDDB01609
  • ACS_NO201530-41-8
  • Show 2D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)0.62
  • pkaN/A
  • LogD (pH=7, predicted)-1.29
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-1.29
  • LogSw (predicted, AB/LogsW2.0)0.41
  • Sw (mg/ml) (predicted, ACD/Labs)0.56
  • No.of HBond Donors3
  • No.of HBond Acceptors7
  • No.of Rotatable Bonds2
  • TPSA98.74
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA rationally-designedoral iron chelator. Its main use is to reduce chronic iron overload in patients who are receiving long-term blood transfusions for conditions such as beta-thalassemia and other chronic anemias.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability70.0
  • Protein binding99.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmHepatic glucuronidation
  • Half life8~16 h
  • ExcretionFecal (84%) and renal (8%)
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityN/A
  • LD50 (rat)N/A
  • LD50 (mouse)N/A